Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

References

• Pelletier N, Casamayor-Pallejà M, De Luca K, Mondière P, Saltel F, Jurdic P, et al. The endoplasmic reticulum is a key component of the plasma cell death pathway. J Immunol 2006; 176: 1340–1347
   PubMed Web of Science ®Google Scholar
• Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519–529
   PubMed Web of Science ®Google Scholar
• Schroder M, Kaufman R-J. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739–789
   PubMed Web of Science ®Google Scholar
• Lin J H, Li H, Yasumura D, Cohen H R, Zhang C, Panning B, et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007; 318: 944–949
   PubMed Web of Science ®Google Scholar
• Rutkowski D T, Kaufman R J. A trip to the ER: coping with stress. Trends Cell Biol 2004; 14: 20–28
   PubMed Web of Science ®Google Scholar
• Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006; 25: 1104–1113
   PubMed Web of Science ®Google Scholar
• Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, et al. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 2007; 16: 618–629
   PubMed Web of Science ®Google Scholar
• Tsai B, Ye Y, Rapoport T A. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 2002; 3: 246–255
   PubMed Web of Science ®Google Scholar
• Ferri K F, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001; 3: E255–E263
   PubMed Web of Science ®Google Scholar
• Lee A H, Iwakoshi N N, Glimcher L H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003; 23: 7448–7459
   PubMed Web of Science ®Google Scholar
• Reimold A M, Lwakoshi N N, Manis J, Vallabhajossyula P, Szomolanyi-Tsuda E, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001; 412: 300–307
   PubMed Web of Science ®Google Scholar
• Carrasco D R, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco D E, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007; 11: 349–360
   PubMed Web of Science ®Google Scholar
• Gardner R C, Assinder S J, Christie G, Mason G G, Markwell R, Wadsworth H, et al. Characterization of peptidyl boronic acid inhibitors of mammalian 20S and 26S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 2000; 346: 447–454
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella V J, Sausville E A, Johnson J, Destree A, Lazarus D D, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, Palombella V J, Elliott P J, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson K C. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005; 4: 686–692
   PubMed Web of Science ®Google Scholar
• Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006; 20: 1341–1352
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Richardson P G, Poulaki V, Tai Y T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
   PubMed Web of Science ®Google Scholar
• Ma M H, Yang H H, Parker K, Manyak S, Friedman J M, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079–4086
   PubMed Web of Science ®Google Scholar
• Obeng E A, Carlson L M, Gutman D M, Harrington W J, Jr, Lee K P, Boise L H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907–4916
   PubMed Web of Science ®Google Scholar
• Rao R V, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, et al. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 2002; 277: 21836–21842
   PubMed Web of Science ®Google Scholar
• Murakami Y, Aizu-Yokota E, Sonoda Y, Ohta S, Kasahara T. Suppression of endoplasmic reticulum stress-induced caspase activation and cell death by the overexpression of Bcl-xL or Bcl-2. J Biochem 2007; 141: 401–410
   PubMed Web of Science ®Google Scholar
• Masud A, Mohapatra A, Lakhani S A, Ferrandino A, Hakem R, Flavell R A. Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis. J Biol Chem 2007; 282: 14132–14139
   PubMed Web of Science ®Google Scholar
• Gu H T, Chen X Q, Gao G X, Dong H J. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7: 2298–2307
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418–5424
   PubMed Web of Science ®Google Scholar
• Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783–1792
   PubMed Web of Science ®Google Scholar
• Qiang Y W, Kitagawa M, Higashi M, Ishii G, Morimoto C, Harigaya K. Activation of mitogen-activated protein kinase through α5/β1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol 2000; 28: 1147–1157
   PubMed Web of Science ®Google Scholar
• Hirota M, Kitagaki M, Itagaki H, Aiba S. Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress. J Toxicol Sci 2006; 31: 149–156
   PubMedGoogle Scholar
• Nawrocki S T, Carew J S, Dunner K, Jr, Boise L H, Chiao P J, Huang P, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510–11519
   PubMed Web of Science ®Google Scholar
• Zhao X, Carnevale K A, Cathcart M K. Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex. J Biol Chem 2003; 278: 40788–40792
   PubMedGoogle Scholar
• Rubinson D A, Dillon C P, Kwiatkowski A V, Sievers C, Yang L, Kopinja J, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401–406
   PubMed Web of Science ®Google Scholar
• Yu C Y, Hsu Y W, Liao C L, Lin Y L. Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. J Virol 2006; 80: 11868–11880
   PubMed Web of Science ®Google Scholar
• Brummelkamp T R, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550–553
   PubMed Web of Science ®Google Scholar
• Lee A H, Iwakoshi N N, Anderson K C, Glimcher L H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946–9951
   PubMed Web of Science ®Google Scholar
• Ohok N, Hattori T, Kitagawa M, Onozaki K, Hayashi H. Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal protein. J Biol Chem 2007; 282: 35687–35694
   PubMed Web of Science ®Google Scholar
• Paddison P J, Hannon G J. RNA interference: the new somatic cell genetics?. Cancer Cell 2002; 2: 17–23
   PubMed Web of Science ®Google Scholar
• Morris J, Dorner A J, Edwards C A, Hendershot L M, Kaufman R J. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J Biol Chem 1997; 272: 4327–4334
   PubMed Web of Science ®Google Scholar
• Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot R T, Remotti H, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Gene Dev 1998; 12: 982–995
   PubMed Web of Science ®Google Scholar
• Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006; 13: 363–373
   PubMed Web of Science ®Google Scholar